Protocol Review & Monitoring System The Protocol Review & Monitoring System (PRMS) at Moffitt Cancer Center facilitates the function of two Scientific Review Committees (SRCs), each staffed with appropriate faculty and scientific representation. Each committee meets once a month, with staggered meetings so that there is an SRC meeting approximately every two weeks. The SRCs provide the review for scientific merit and prioritization and monitor scientific progress for all protocols at the Cancer Center. SRC approval is required prior to IRB submission and the IRB will not consider a research study from the Cancer Center that has not been approved by the Moffitt Cancer Center SRC. The SRCs have reviewed between 180 and 200 new protocols each year of the grant for scientific merit. Protocols that have been previously peer reviewed by recognized peer-review agencies are expedited through the SRC process, but are reviewed administratively by the Chair or his designee. The committees review all ongoing clinical research studies for scientific progress and have the authority to suspend and close studies that are not making scientific progress towards their objectives. The Cancer Center is in the process of implementing the Oncore? clinical trials management software that will aid the PRMS in the administrative tracking of all research studies (pending and ongoing), as well as facilitate the committee process by helping to coordinate the committee membership, agendas, decisions and correspondence.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-10
Application #
7579067
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-02-01
Budget End
2009-01-31
Support Year
10
Fiscal Year
2008
Total Cost
$135,077
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Karolak, Aleksandra; Rejniak, Katarzyna A (2018) Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue. Bull Math Biol :
Karolak, Aleksandra; Estrella, Veronica C; Huynh, Amanda S et al. (2018) Targeting Ligand Specificity Linked to Tumor Tissue Topological Heterogeneity via Single-Cell Micro-Pharmacological Modeling. Sci Rep 8:3638
Barata, Anna; Gonzalez, Brian D; Sutton, Steven K et al. (2018) Coping strategies modify risk of depression associated with hematopoietic cell transplant symptomatology. J Health Psychol 23:1028-1037
Li, Qian; Balagurunathan, Yoganand; Liu, Ying et al. (2018) Comparison Between Radiological Semantic Features and Lung-RADS in Predicting Malignancy of Screen-Detected Lung Nodules in the National Lung Screening Trial. Clin Lung Cancer 19:148-156.e3
Kazi, Aslamuzzaman; Xiang, Shengyan; Yang, Hua et al. (2018) GSK3 suppression upregulates ?-catenin and c-Myc to abrogate KRas-dependent tumors. Nat Commun 9:5154
McWilliams, Robert R; Wieben, Eric D; Chaffee, Kari G et al. (2018) CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev 27:1364-1370
Ctortecka, Claudia; Palve, Vinayak; Kuenzi, Brent M et al. (2018) Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells. Mol Cell Proteomics 17:2434-2447
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
Schmit, Stephanie L; Edlund, Christopher K; Schumacher, Fredrick R et al. (2018) Novel Common Genetic Susceptibility Loci for Colorectal Cancer. J Natl Cancer Inst :
Kang, Sokbom; Thompson, Zachary; McClung, E Claire et al. (2018) Gene Expression Signature-Based Prediction of Lymph Node Metastasis in Patients With Endometrioid Endometrial Cancer. Int J Gynecol Cancer 28:260-266

Showing the most recent 10 out of 1254 publications